ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
사전등록 바로가기
 

논문 상세

Home > 논문 상세
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

이전

다음

35권 3호
Share

한의학과 개인맞춤의학에 대한 소고; 변증논치에 근거한 ‘증 기반 개인맞춤의학’

A Review on Korean Medicine and Personalized Medicine: Syndrome-based Personalized Medicine on the Basis of Syndrome Differentiation and Treatment

대한한의학회지 / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2014, v.35 no.3, pp.40-48
한재민 (경희대학교)
양웅모 (경희대학교)
한재민, & 양웅모. (2014). 한의학과 개인맞춤의학에 대한 소고; 변증논치에 근거한 ‘증 기반 개인맞춤의학’. 대한한의학회지, 35(3), 40-48.
  • 다운로드 수
  • 조회수

Abstract

Objectives: This study aimed to review the characteristics of personalized medicine and Korean medicine, and the correlation between personalized medicine and Korean medicine. Methods: We investigated various studies in PubMed, Scopus and domestic Korean medicine journals. In addition, we discussed the topic based on literature. Results: Western medicine developed as evidence-based medicine. However, its limitations are being reached, so a new paradigm of medicine is needed. As a result, personalized medicine has appeared. Recently, through the development of human genomics, personalized medicine has been researched on the basis of individual genetic characteristics. Korean medicine has developed with a unique holistic approach and treats not the disease itself but the patient’s body. Its characteristic is well expressed through syndrome differentiation and treatment. Syndrome differentiation represents the nature of person-centered medicine and becomes the root of personalized medicine. Conclusions: Compared with genome-based personalized medicine of Western medicine, Korean medicine could be classified as syndrome-based personalized medicine. It would be great to apply this characteristic to clinical practices.

keywords
Korean medicine, personalized medicine, tailored care, syndrome differentiation and treatment, syndrome-based personalized medicine


참고문헌

1

1. Ahn HS. Introduction to Evidence-based Medicine. Journal of Korean Society of Quality Assurance in Health Care. 2005;12(2):9-16.

2

2. Lim YC. A Critical Contemplation on ‘Personalized Medicine’ of Modern Medicine. The Korean Association for Philosophy of Medicine. 2012;13:135-162.

3

3. Hong KW, Oh B. Overview of personalized medicine in the disease genomic era. BMB Rep. 2010;43(10):643648.

4

4. Lee SW, Lee KB, Kang JW, Choi JH, Oh JH. Trends in Personalized Medicine Research, Communications of the Korean Institute of Information Scientists and Engineer. 2011;29(4):19-25.

5

5. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, et al. Clinical Pharmacogenetics and Potential Application in Personalized Medicine. Curr Drug Metab. 2008;9(8):738-84.

6

6. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-4.

7

7. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature. 2009;461(7265):724-6.

8

8. Fung EY, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, et al. Analysis of 17autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 2009;10(2):188-91.

9

9. Dai J, Fang J, Sun S, Chen Q, Cao H, Zheng N, et al. ZHENG-Omics Application in ZHENG Classification and Treatment: Chinese Personalized Medicine. Evid Based Complement Alternat Med. 2013;2013:235969.

10

10. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420-5.

11

11. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine:what it is and what it isn’t. BMJ. 1996;312(7023):71-2.

12

12. Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ. 1995;310(6987):1122-6.

13

13. Tonelli MR. The philosophical limits of evidence-based medicine. Acad Med. 1998;73(12):1234-40.

14

14. Goldman JJ, Shih TL. The limitations of evidence-based medicine--applying population-based recommendations to individual patients. Virtual Mentor. 2011;13(1):26-30.

15

15. Jain KK. Textbook of Personalized Medicine. New York:Springer. 2009:1-136.

16

16. Straus SE, McAlister FA. Evidence-based medicine: a commentary on common criticisms. CMAJ. 2000 Oct 3;163(7):837-41.

17

17. Cohen AM, Stavri PZ, Hersh WR. A categorization and analysis of the criticisms of Evidence-Based Medicine. Int J Med Inform. 2004;73(1):35-43.

18

18. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001;19(12):491-6.

19

19. Ray O. The revolutionary health science of psychoendoneuroimmunology: a new paradigm for understanding health and treating illness. Ann N Y Acad Sci. 2004;1032:35-51.

20

20. Yan Q. Toward the integration of personalized and systems medicine: challenges, opportunities and approaches. Personalized Medicine. 2011;8(1):1-4.

21

21. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration:prevalence of related drug use. Pharmacotherapy. 2008;28(8):992-8.

22

22. Novelli G. Personalized genomic medicine. Intern Emerg Med. 2010;5(1):81-90.

23

23. Lee SW, Lee KB, Kang JW, Choi JH, Oh JH. Trends in Personalized Medicine Research, Communications of the Korean Institute of Information Scientists and Engineer. 2011;29(4):19-25.

24

24. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. QJM. 2000;93(7):391-423.

25

25. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-78.

26

26. Gispen WH, Adan RAH. Preface. Eur J Pharmacol. 2000;410(2-3):105.

27

27. Shin JG, Cha IJ. Pharmacogenetics: A Principle for the Personalized Pharmacotherapy. Inje Medical Journal. 2002;23(2):71-83.

28

28. Yan Q. Pharmacogenomics in Drug Discovery and Development : From Bench to Bedside. Clifton:Methods Mol Biol. 2008;448:5-7.

29

29. Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complement Ther Med. 2012;20(1-2):93-9.

30

30. Wang X, Sun H, Zhang A, Sun W, Wang P, Wang Z. Potential role of metabolomics apporoaches in the area of traditional Chinese medicine: as pillars of the bridge between Chinese and Western medicine. J Pharm Biomed Anal. 2011;55(5):859-68.

31

31. Kim WH. Hanuihak Wonron. Seoul:Seongbosa. 2001:32-34.

32

32. Lesko LJ. Personalized medicine: elusive dream or imminent reality?. Clin Pharmacol Ther. 2007;81(6):807-16.

33

33. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55.

34

34. Franzel B, Schwiegershausen M, Heusser P, Berger B. Individualised medicine from the perspectives of patients using complementary therapies: a meta-ethnography approach. BMC Complement Altern Med. 2013;13:124.

  • 다운로드 수
  • 조회수
  • 0KCI 피인용수
  • 0WOS 피인용수

권호 내 다른 논문

추천 논문

상단으로 이동

권호 목록

소개

규정 및 지침

게시판

대한한의학회지

  학술지 홈페이지 이용 환경은   크롬 브라우저 사용을 권장합니다.

대한한의학회지

논문 투고 OA 정책